In Case You Missed: Advancing Science in the Management of Demodex Blepharitis
This activity is supported by an educational grant from Tarsus Pharmaceuticals, Inc.
Overview
Provider Statement
This continuing education activity is provided by
Educational Partner
Support Statement
This activity is supported by an educational grant from Tarsus Pharmaceuticals, Inc.
Activity Description
Recent US studies have reported Demodex blepharitis infestation rates of 55% to 58% in eye care clinical patients. However, patients with Demodex blepharitis may go undiagnosed or misdiagnosed due to overlapping symptoms seen in dry eye disease and other ocular surface or lid margin disorders. Treatment can also be challenging as there are currently no FDA-approved therapies and most conventional options treat the symptoms of disease but not the underlying cause. Emerging therapeutic options are currently under clinical investigation that treat and target the underlying cause of Demodex blepharitis offering the potential to resolve disease and improve patient quality of life measures. In this continuing medical education activity, experts in the field review the burden and prevalence of Demodex blepharitis, evaluate the efficacy of conventional treatment strategies, and assess the latest clinical evidence pertaining to emerging therapies that hold promise in the treatment of this disease.
Target Audience
The intended audience for this activity is ophthalmologists, optometrists, pharmacists, and other health care professionals involved in treating Demodex blepharitis.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the burden and prevalence of Demodex blepharitis and the efficacy of conventional therapies used to treat the condition.
- Assess new clinical evidence about emerging therapies that hold promise in the treatment of Demodex blepharitis.
Activity Chair
Elizabeth Yeu, MD
Cornea, Cataract, External Disease and Refractive Surgery
Virginia Eye Consultants/EyeCare Partners
Medical Director, CVP Mid-Atlantic Surgery Center
Assistant Professor, Eastern Virginia Medical School
Norfolk, VA
Faculty
Marjan Farid, MD
Clinical Professor of Ophthalmology
Director of Cornea, Cataract and Refractive Surgery
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, CA
Paul M. Karpecki, OD, FAAO
Director, Cornea Services
Kentucky Eye Institute
Lexington, KY
Planners/Reviewers
Ashay Bhatwadekar, PhD, RPh
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Accreditation
Purdue University is approved by the Council on Optometric Practitioner Education (COPE) as an administrator/provider of continuing education (CE).
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Credit Designation
This enduring material is COPE-accredited for 1.0 continuing education credits and is approved for one (1) year from the date of original release, December 30, 2022, to December 30, 2023.
COPE Course ID #: 82272-TD
COPE Activity ID #: 125223
Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-9999-22-036-H01-P, effective 12/30/2022. This is a knowledge-based activity, and there is no fee to attend.
Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.
This enduring material is approved for 1 year from the date of original release, December 30, 2022, to December 30, 2023.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Purdue University will issue a CE Certificate or Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Statement of Continuing Pharmacy Education Credit.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Marjan Farid, MD
Advisor: Allergan, Bausch + Lomb, Bio-Tissue, Dompé, Johnson & Johnson Vision, Kala, Novartis, Orasis, Sun, Tarsus, Zeiss
Consultant: Allergan, Bausch + Lomb, Bio-Tissue, Dompé, Johnson & Johnson Vision, Kala, Novartis, Orasis, Sun, Tarsus, Zeiss
Paul M. Karpecki, OD, FAAO
Consultant: AdOM, Alcon, Aldeyra, Allergan/AbbVie, Atlas, Azura, Bausch + Lomb, Bio-Tissue, Bruder, Cambium, Imprimis, Novartis, Oasis Medical, Oculus, OCuSOFT, Olympic Ophthalmics, Oyster Point, RegenerEyes, Rendia, Santen, ScienceBased Health, Scope, Sight Sciences, Silk Technologies, Sun, Surface, Tarsus, Thea, Vital Tears
Individual Stocks and Stock Options: Tarsus
Elizabeth Yeu, MD
Consultant: AcuFocus, Advances Vision Group, Allergan, Aurion, Avellino, Bausch + Lomb/Valeant, Bio-Tissue, BlephEx, Bruder, BVI, CorneaGen, Dompé, Expert Opinion, EyePoint, Glaukos, Guidepoint, Iveric Bio, Johnson & Johnson Vision, Kala, Layer Bio, Lensar, Melt, Merck, New World Medical, Novartis, Ocular Science, OCuSOFT, Omeros, Orasis, ScienceBased Health, Sight Sciences, STAAR, Surface, Tarsus, Théa, Visus, Zeiss
Speaker Contracted by Ineligible Company: Alcon
Independent Research Contractor: AcuFocus, Alcon, Bio-Tissue, New World Medical, Ocular Science, Tarsus
Individual Stocks and Stock Options: Advanced Vision Group, Aurion, Avellino, BlephEx, Centricity, CorneaGen, Equinox, Expert Opinion, Layer Bio, Mati, Melt, Modernizing Medicine, Ocular Science, Orasis, STAAR, Tarsus, Visus
Planners/Reviewers report the following relationship(s)
Ashay Bhatwadekar, PhD, RPh
Consultant: Guidepoint, Ono Pharmaceutical
Independent Research Contractor: National Institute of Health
Ad hoc Pharmacist: CVS Health/Aetna
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.
The material presented at or in any Purdue University and Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Purdue University or Vindico Medical Education. Neither Purdue University, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
COPE Questions?
Contact us at pharmacy-cecr@purdue.edu
CME/CPE Questions?
Contact us at CME@VindicoCME.com